Savara is a single-asset rare-respiratory company sitting one agency decision away from becoming a commercial orphan-drug operator. The inhaled granulocyte-macrophage colony-stimulating factor candidate, branded MOLBREEVI, already has a published pivotal result and a Priority Review clock that now points to late November. The equity is no longer a clinical-data story. It is a manufacturing-and-review story after last year's refuse-to-file letter and this spring's major-amendment extension. That sequence is the entire investment debate. A clean approval converts a pre-revenue platform into a first-in-class franchise in autoimmune pulmonary alveolar proteinosis. Another chemistry delay leaves a hired commercial organization burning cash against a still-unapproved file.
Cash at mid-year sat near $173 million. Funded Hercules debt was about $30 million. Operating spend is already climbing as the commercial team is hired, and general and administrative costs nearly doubled versus the year-ago quarter. That spend only makes sense if approval arrives on the current clock. The counterargument is that the agency already sent the file back once for chemistry and manufacturing completeness, so the market is paying a launch multiple for a review that is not yet clean. Access to as much as $150 million of approval-gated Hercules and RTW capital is real optionality, not cash in the bank.
Second-quarter net loss widened as share-based pay and launch hiring hit the income statement. Research spending barely grew because the trial is done and the file is in. The question the next two months resolve is whether the agency treats the resubmitted manufacturing package as approvable, or whether another complete-response cycle forces a dilutive raise into a still-pre-revenue franchise.